EyePoint Pharmaceuticals, Inc. — Director's Dealing 2022

Feb 11, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: EyePoint Pharmaceuticals, Inc. (EYPT)
CIK: 0001314102
Period of Report: 2022-02-09

Reporting Person: Jones David Scott (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-02-09	Common Stock	M	4966.00	$0.00	Acquired	14097.00	Direct
2022-02-09	Common Stock	F	1473.00	$10.13	Disposed	12624.00	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-02-09	Restricted Stock Units	$0.00	A	15000.00	Acquired		Common Stock (15000.00)	Direct
2022-02-09	Restricted Stock Units	$0.00	M	4966.00	Disposed		Common Stock (4966.00)	Direct
2022-02-09	Stock Option (Right to Buy)	$10.13	A	60000.00	Acquired	2032-02-09	Common Stock (60000.00)	Direct

Footnotes

F1: Includes 886 shares acquired on July 30, 2021 and 865 shares acquired on January 31,2022 pursuant to EyePoint's 2019 Employee Stock Purchase Plan.

F2: No shares were sold - these shares were withheld by the issuer to satisfy tax withholding requirements in connection with the Reporting Person's exercise of his withholding right following the vesting of the restricted stock units

F3: The restricted stock units will vest in three ratable annual installments beginning February 9, 2023.

F4: The restricted stock units vest in three ratable annual installments beginning February 9, 2022.

F5: The option to purchase will vest and become exercisable as follows: 25% at February 9th, 2023 and the remainder ratably, on a monthly basis, over the remaining three years.